Forward P/E of Retrophin, Inc.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
|BTX BioTime, Inc.||NYSEMKT > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||3.86|
|RADA RADA Electronic Industries Ltd.||NASDAQ > Consumer Non-Durables > Electronic Components||3.87|
|CRUS Cirrus Logic, Inc.||NASDAQ > Technology > Semiconductors||3.87|
|TXN Texas Instruments Incorporated||NASDAQ > Technology > Semiconductors||3.87|
|ARWR Arrowhead Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||3.87|
|LPTH LightPath Technologies, Inc.||NASDAQ > Technology > Semiconductors||3.88|
|RTRX Retrophin, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||3.88|
|MAG MAG Silver Corporation||NYSEMKT > Basic Industries > Precious Metals||297.63|
|ORI Old Republic International Corporation||NYSE > Finance > Property-Casualty Insurers||762.43|
|WMIH WMIH Corp.||NASDAQ > Finance > Finance: Consumer Services||812.31|
|AMG Affiliated Managers Group, Inc.||NYSE > Finance > Investment Managers||966.10|
|HUNT Hunter Maritime Acquisition Corp.||NASDAQ > Transportation > Oil Refining/Marketing||1,687.50|
|IOR Income Opportunity Realty Investors, Inc.||NYSEMKT > Consumer Services > Real Estate Investment Trusts||4,830.80|